Cargando…

Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients

AIM: Our aim is to compare the toxicity, pelvic nodal relapse, and overall survival of whole bladder irradiation only to the standard technique of whole pelvis irradiation followed by bladder boost in patients with muscle-invasive bladder carcinoma undergoing bladder preservation protocol. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arafat, Waleed, Darwish, Azza, Naoum, George E, Sameh, Wael, Husseiny, Gamal El, Abd-El-Gawad, Fathy, Samir, Mostafa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102689/ https://www.ncbi.nlm.nih.gov/pubmed/27899955 http://dx.doi.org/10.3332/ecancer.2016.682

Ejemplares similares

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer
por: Joung, Jae Young, et al.
Publicado: (2008)

The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer
por: Miyata, Haruka, et al.
Publicado: (2020)

Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: Shahbaz, Muhammad, et al.
Publicado: (2020)

Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer
por: Mohammed, Ayatallah Ali Youssief, et al.
Publicado: (2023)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience
por: Polineni, Praneet, et al.
Publicado: (2021)

Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis
por: Su, Xiaozhe, et al.
Publicado: (2023)

The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer
por: Russell, Christopher M., et al.
Publicado: (2016)

Trimodal Therapy Using an MR–guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer
por: Liveringhouse, Casey, et al.
Publicado: (2023)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis
por: Ding, Hui, et al.
Publicado: (2020)

Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer
por: Guo, Yadong, et al.
Publicado: (2019)

A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer
por: Portner, R., et al.
Publicado: (2021)

Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer
por: Bachir, Bassel G., et al.
Publicado: (2017)

Conditional survival of trimodal therapy for nonmetastatic muscle‐invasive bladder cancer: A SEER database analysis
por: Shangguan, Wentai, et al.
Publicado: (2022)

Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy
por: Magliocco, Anthony M., et al.
Publicado: (2022)

Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
por: Lee, Cheng-Yen, et al.
Publicado: (2014)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review
por: Decazes, Pierre, et al.
Publicado: (2021)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Trimodal therapy in T2‐4aN0M0 bladder cancer––How to select the best candidate?
por: Gofrit, Ofer N., et al.
Publicado: (2020)

Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle‐invasive bladder cancer
por: Krishnatry, Rahul, et al.
Publicado: (2023)

Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes
por: Garcia, Maurice M., et al.
Publicado: (2014)

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis
por: Qiu, Junlan, et al.
Publicado: (2022)

Characterization of positioning uncertainties in PET‐CT‐MR trimodality solutions for radiotherapy
por: Hinault, Pauline, et al.
Publicado: (2022)

Could Concurrent Capecitabine with Hypofractionated Radiotherapy in Elderly Patients with Muscle-Invasive Bladder Cancer be an Option?
por: Youssief, Ayatallah A, et al.
Publicado: (2022)

Bladder Preservation with Primary Closure in an Adolescent Girl with Bladder Exstrophy
por: Aslan, Yılmaz, et al.
Publicado: (2017)

Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes
por: Garcia, Maurice M., et al.
Publicado: (2016)

Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis
por: Kim, Yeon Joo, et al.
Publicado: (2017)

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016)

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?
por: Smelser, Woodson Wade, et al.
Publicado: (2017)

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
por: Hamad, Judy, et al.
Publicado: (2020)

Differences in Cancer-Specific Mortality after Trimodal Therapy for T2N0M0 Bladder Cancer according to Histological Subtype
por: Barletta, Francesco, et al.
Publicado: (2022)

Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis
por: Zhou, Yi-Xin, et al.
Publicado: (2023)

Bladder emptying flow rate as a function of bladder volume.
por: Spencer, R. P., et al.
Publicado: (1971)

Implantable Bladder Sensors for Long-term Monitoring of Bladder Volume
por: Kim, Su Jin
Publicado: (2015)

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder
por: Michaelson, M D, et al.
Publicado: (2004)

Impact of bladder volume on treatment planning and clinical outcomes of radiotherapy for patients with cervical cancer
por: Ma, Shanshan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1jl1uisqvodsoptb8m7jcfpm5r